Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinyang Pian is a Traditional Chinese Medicine (TCM) tablet formulation developed by The First Affiliated Hospital of Guangzhou University of Chinese Medicine. It is specifically designed for the treatment of chronic heart failure (CHF) secondary to coronary heart disease, particularly in patients presenting with the TCM syndrome of Qi and Yang deficiency, blood stasis, and water retention. The therapeutic approach of Xinyang Pian involves warming the heart yang, replenishing qi, and promoting blood circulation to resolve water retention and improve cardiac function. It is currently being evaluated in clinical trials to establish its efficacy and safety profile as a treatment for heart failure within the framework of integrative medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xinyang Pian.